In today’s recent session, 0.52 million shares of the Autolus Therapeutics plc ADR (NASDAQ:AUTL) have been traded, and its beta is 2.07. Most recently the company’s share price was $1.62, and it changed around $0.0 or 0.00% from the last close, which brings the market valuation of the company to $431.11M. AUTL at last check was trading at a discount to its 52-week high of $6.48, offering almost -300.0% off that amount. The share price’s 52-week low was $1.56, which indicates that the recent value has risen by an impressive 3.7% since then. We note from Autolus Therapeutics plc ADR’s average daily trading volume that its 10-day average is 1.3 million shares, with the 3-month average coming to 1.24 million.
Autolus Therapeutics plc ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.00. If we narrow it down even further, the data shows that 0 out of 10 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended AUTL as a Hold, whereas 8 deemed it a Buy, and 0 rated it as Underweight. Autolus Therapeutics plc ADR is expected to report earnings per share of -0.26 for the current quarter.
Autolus Therapeutics plc ADR (NASDAQ:AUTL) trade information
The performance over the last five days has remained in the red territory. The rise to weekly highs of 2.0150 on recent trading dayincreased the stock’s daily price by 19.6%. The company’s shares are currently down -31.06% year-to-date, but still down -16.49% over the last five days. On the other hand, Autolus Therapeutics plc ADR (NASDAQ:AUTL) is -9.50% down in the 30-day period. We can see from the shorts that 9.13 million shares have been sold at a short interest cover period of 7.04 day(s).
The consensus price target as assigned by Wall Street analysts is $7.6, which translates to bulls needing to increase their stock price by 78.68% from its current value. Analyst projections state that AUTL is forecast to be at a low of $7.6 and a high of $7.6.
Autolus Therapeutics plc ADR (AUTL) estimates and forecasts
The year-over-year growth rate is expected to be 214.45%, up from the previous year.
Consensus estimates provided by 5 financial analysts predict the company will bring in an average of 1.42M in revenue for the current quarter. 5 analysts expect Autolus Therapeutics plc ADR to make 5.34M in revenue for the current ending quarter. Analysts predict that the company’s current quarter sales will drop, forecast at -85.98%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 21.36%. Autolus Therapeutics plc ADR earnings are expected to increase by -2.73% in 2025, but the outlook is positive 28.61% per year for the next five years.
Autolus Therapeutics plc ADR (NASDAQ:AUTL)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 18.09% of Autolus Therapeutics plc ADR shares, and 86.12% of them are in the hands of institutional investors. The stock currently has a share float of 105.14%. Autolus Therapeutics plc ADR stock is held by 145.0 institutions, with SYNCONA PORTFOLIO LTD being the largest institutional investor. By 2024-06-30, it held 8.0243% of the shares, which is about 21.35 million shares worth $74.29 million.
BLACKSTONE INC., with 7.7006% or 20.49 million shares worth $71.29 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Health Care Fund and Fidelity Small Cap Growth Fund were the top two Mutual Funds as of Oct 31, 2024. The former held 19.36 shares worth $31.16 million, making up 7.27% of all outstanding shares. On the other hand, Fidelity Small Cap Growth Fund held roughly 2.57 shares worth around $4.14 million, which represents about 0.97% of the total shares outstanding.
